Sugi Predict

Sugi Predict / Compounds / SCHEMBL261614

SCHEMBL261614

SCHEMBL261614

CN[C@H]1CC[C@H](CO)CC1

nearest known ligand 0.34

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 6/20 0.34
▸ ESR2 Q92731 6/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CHRM3 P20309 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261822 1.00 ESR1 (0.34) ESR1ESR2CYP3A4CYP2C9CHRM3
SCHEMBL5042886 0.85 — —
SCHEMBL13355187 0.85 — —
SCHEMBL22418637 0.85 — —
SCHEMBL764231 0.85 — —
SCHEMBL23541550 0.83 EPHX1 (0.36) ESR1ESR2CYP3A4CYP2C9CYP2D6
Hydrochloric Acid SCHEMBL1584359 0.83 EPHX2 (0.30) —
Alcohol SCHEMBL9949940 0.80 — —
SCHEMBL16840999 0.80 ESR2 (0.38) ESR2
SCHEMBL19184740 0.80 ESR2 (0.38) ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062410-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-12398141-B2 JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) 2025-08-26 — — US disclosed
US-12281111-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same ACLARIS THERAPEUTICS, INC. (US) 2025-04-22 — — US disclosed
CN-119707989-A Ola maleate Synthesis method of tinib 新未来(天津)生物科技有限公司 2025-03-28 — — CN disclosed
CN-118598877-A Ola maleate preparation method of tenib 艾美科健（中国）生物医药有限公司 2024-09-06 — — CN disclosed
CN-114605420-B Synthesis method of olatinib maleate 江苏慧聚药业股份有限公司 2024-07-12 — — CN disclosed
CN-113631557-B JAK kinase inhibitor, preparation method thereof and application thereof in medicine field 上海华汇拓医药科技有限公司 2024-03-15 — — CN disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 — — US disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 — — US disclosed
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME ACLARIS THERAPEUTICS, INC. 2024-02-29 — — US disclosed
CN-1798558-A Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor HOFFMANN LA ROCHE (CH) 2006-07-05 — — CN disclosed
EP-1633355-A1 BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2006-03-15 — — EP disclosed
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors ACKERMANN JEAN (CH) 2005-08-11 — — US disclosed
US-6858651-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-02-22 — — US disclosed
WO-2004105755-A1 BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2004-12-09 — — WO disclosed
US-20040242576-A1 Urea substituted benzothiazoles HOFFMANN-LA ROCHE INC. 2004-12-02 — — US disclosed
CN-1468214-A Novel derivatives of aminocyclohexane - 2004-01-14 — — CN disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 — — EP disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281111-B2 Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same JAK3, JAK1, JAK2 ESR1 4135/4885ESR2 3828/4885CYP3A4 1926/4885
US-20260062410-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 ESR1 3069/4885ESR2 3351/4885CYP3A4 2505/4885
US-20240067643-A1 SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME JAK3, JAK1, JAK2 ESR1 4135/4885ESR2 3828/4885CYP3A4 1926/4885
US-12398141-B2 JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine JAK1, JAK2, JAK3 ESR1 4178/4885ESR2 3858/4885CYP3A4 1614/4885
US-20040242576-A1 Urea substituted benzothiazoles UTS2R, ADRB2, TBXA2R ESR1 434/4885ESR2 69/4885CYP3A4 531/4885
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 ESR1 1849/4885ESR2 701/4885CYP3A4 499/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 ESR1 1849/4885ESR2 701/4885CYP3A4 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.